Barclays analyst Carter Gould maintained a Hold rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at $44.16.
According to TipRanks, Gould is a 2-star analyst with an average return of 1.1% and a 52.38% success rate. Gould covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Biogen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $52.64 average price target, which is a 19.20% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $54.46 and a one-year low of $40.72. Currently, Pfizer has an average volume of 21.88M.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year. Most recently, in December 2022, Douglas Lankler, the EVP of PFE bought 191,862.00 shares for a total of $5,139,071.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer CFO says increasing investments behind launch products and pipeline
- Pfizer expects revenue from COVID-19 products to grow in 2024
- Pfizer says FY23 guidance does not anticipate any share repurchases